



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 04/21/2022 19:20
Last Report Issued 05/03/2021 13:27

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 8088B
Patient ID 8088B
Chain 21000629
DOB Not Given
Sex Not Given
Workorder 21000629
Received 05/03/2021

Lab ID 21000629-001
Matrix Blood
Patient Name 8088B
Patient ID 8088B
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

8088B Qsymia®, Blood

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Phentermine Peak plasma concentrations were 49 ng/mL phentermine following a single oral dose of Qsymia® (15 mg phentermine IR/92 mg topiramate CR). The blood to plasma ratio for phentermine is not known.	None Detected	ng/mL	5.0	
---	---------------	-------	-----	--

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Topiramate Peak plasma concentrations were 1020 ng/mL topiramate following a single oral dose of Qsymia® (15 mg phentermine IR/92 mg topiramate CR). The blood to plasma ratio for topiramate varies depending on the concentration, but is typically greater than 2.	None Detected	ng/mL	200	
--	---------------	-------	-----	--

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.